Gleason Group’s Actuate Therapeutics ACTU Stock Holding History

Gleason Group’s Portfolio ACTU Stock Details ACTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$14.8K	Hold	19,028	–	–	﹤0.01%	184
2026 Q2	$29.1K	Hold	19,028	–	–	﹤0.01%	161
2026 Q1	$52.1K	Hold	19,028	–	–	0.01%	121
2025 Q4	$116K	Hold	19,028	–	–	0.01%	89
2025 Q3	$127K	Hold	19,028	–	–	0.01%	78
2025 Q2	$116K	Buy	+19,028	New	+$166K	0.01%	81

Other funds holding ACTU

Sowell Financial Services North Little Rock, Arkansas $3.12B AUM 22.73% 1-Year Est. Return

GRWP

Green Ridge Wealth Planning Montville, New Jersey $249M AUM 26.89% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Gleason Group's ACTU Position: Q3 2026 in Review

Gleason Group held its Actuate Therapeutics (ACTU) position steady in Q3 2026 at 19,028 shares worth $14.8K. The position accounts for ﹤0.01% of the portfolio, ranked #184.

Gleason Group first reported a position in ACTU in Q2 2025 and has held it in 6 quarters since. The position peaked at $127K in Q3 2025. 6 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

Gleason Group held 19,028 shares of Actuate Therapeutics worth $14.8K as of Q3 2026.
Gleason Group left its Actuate Therapeutics share count unchanged in Q3 2026.
Actuate Therapeutics made up ﹤0.01% of Gleason Group's portfolio in Q3 2026, its #184 holding.
Gleason Group first reported a position in Actuate Therapeutics in Q2 2025 and has held it in 6 quarters since.
Gleason Group's Actuate Therapeutics position peaked at $127K in Q3 2025.
6 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Gleason Group's 13F filing for Q3 2026, filed 15 Oct 2026.